NMN and NR in Adolescents Ages 12 to 17: What Parents and Clinicians Need to Know About Off-Label Use

What Are NMN and NR, and Why Do Adolescents Encounter Them?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors, meaning the body converts them into nicotinamide adenine dinucleotide, a coenzyme involved in energy metabolism, DNA repair, and sirtuin signaling. Adolescents encounter these compounds primarily through social media marketing, biohacking communities, and, occasionally, through parents who take them for longevity or metabolic reasons.

NAD+ levels decline with age in adult tissues. This age-related decline is the central rationale behind supplementation in adults. Whether the same decline occurs meaningfully in healthy 12-to-17-year-olds is not established, and the question matters because the theoretical justification for use in adolescents is much weaker than in middle-aged adults. Yoshino et al. (2021) in Science demonstrated NAD+ restoration effects of NMN in postmenopausal women with prediabetes, a population whose baseline NAD+ status differs fundamentally from that of healthy teenagers.

How NMN and NR Are Converted to NAD+

NR enters cells via nucleoside transporters and is phosphorylated by NR kinase 1 or 2 (NRK1/2) to NMN. NMN is then adenylated by NMNAT enzymes to produce NAD+. NMN can also enter cells directly, though the dominant route in human tissue remains debated. A 2023 pharmacokinetic study published in npj Aging confirmed that oral NMN raises whole-blood NAD+ within two hours of ingestion in adult subjects, with peak elevations of roughly 40 percent above baseline at 300 mg doses.

Why Adolescents Are Biologically Different

Adolescence involves rapid cell proliferation, hormonal axis maturation, and active synaptic pruning in the prefrontal cortex. NAD+ participates in PARP-mediated DNA repair and in the signaling activity of CD38, an enzyme highly expressed in immune cells. Altering NAD+ flux in a developing organism is not equivalent to doing so in a fully matured adult. This biological distinction is not a reason to categorically prohibit use, but it does mean that adult tolerability data cannot be extrapolated without caution. The FDA's guidance on pediatric drug development consistently notes that children and adolescents are not simply small adults.

FDA Regulatory Status and the 2022 Enforcement Action

The FDA does not approve dietary supplements before they reach market. Both NMN and NR have been sold under the Dietary Supplement Health and Education Act (DSHEA) of 1994. In late 2022, the FDA sent a warning letter to at least one NMN manufacturer asserting that NMN was previously investigated as a new drug (IND 157,648) and therefore cannot legally be marketed as a dietary supplement under 21 U.S.C. 321(ff)(3)(B). That enforcement position is documented in FDA correspondence available at the agency's website.

For adolescents, this regulatory ambiguity matters. If NMN is reclassified as a drug ingredient, its availability in over-the-counter products could change, which would further limit the already thin evidentiary base guiding off-label clinical use in teens.

NR, by contrast, has not faced the same enforcement scrutiny and retains a generally recognized dietary supplement status. ChromaDex's NIAGEN (NR) received FDA GRAS notification in 2016, and NR products remain freely available. Still, GRAS status pertains to food safety, not to therapeutic efficacy or pediatric dosing appropriateness.

What "Off-Label" Means in This Context

Off-label prescribing refers to a clinician recommending a drug or supplement for a population, dose, or indication not covered by an approved label. Because NMN has no approved label and NR's label does not include adolescents, any clinical recommendation to a 12-to-17-year-old is, by definition, off-label. FDA guidance on off-label use permits physicians to use professional judgment, but the absence of pediatric data places the burden of justification squarely on the recommending clinician.

What Adult Clinical Trials Actually Show

Adult evidence is the only human evidence available. Summarizing the landmark trials helps establish the ceiling of confidence that can be cautiously, partially, extended to adolescent use discussions.

Yamamoto et al. 2023 Dose-Escalation RCT

The most thorough adult safety study to date enrolled 80 healthy Japanese men aged 20 to 65 and tested NMN at 300, 600, and 1,200 mg/day for 12 weeks. No serious adverse events were recorded at any dose. Mild gastrointestinal complaints occurred in fewer than 10 percent of participants across all groups. Whole-blood NAD+ concentrations rose in a dose-dependent manner, with the 1,200 mg/day arm achieving roughly 38 percent elevation from baseline. The full study is indexed on PubMed.

This dose-escalation data is referenced frequently in clinical conversations about NMN. The study's upper bound of 1,200 mg/day has become an informal safety reference, though applying it to adolescents requires recognizing that none of the 80 participants were under 20 years of age.

Yoshino et al. 2021 Women With Prediabetes

A randomized, placebo-controlled trial published in Science assigned 25 postmenopausal women with prediabetes or overweight to 250 mg/day NMN or placebo for 10 weeks. NMN improved muscle insulin signaling, specifically raising expression of genes encoding insulin receptor substrate 1 (IRS1) and GLUT4 in skeletal muscle biopsies. The PubMed listing confirms the N, duration, and metabolic outcomes.

The metabolic profile of postmenopausal women with prediabetes shares nothing with a 14-year-old athlete. Importing these findings into a pediatric context would require mechanistic bridging studies that do not yet exist.

NR Trials in Adults: Elysium BASIS and ChromaDex Studies

NR has been tested in multiple adult populations. Martens et al. (2018) in Nature Communications (N=120, healthy older adults, 500 mg/day NR for 6 weeks) showed that NR raised whole-blood NAD+ by approximately 40 percent compared with placebo, with no significant adverse effects. Blood pressure, lipid panels, and hepatic enzymes remained within normal limits. Again, participants were adults, with a mean age in the mid-60s.

A Clinical Decision Framework for Adolescent NMN/NR Requests

When a parent or adolescent patient asks about NMN or NR, the clinician faces four distinct questions that should be worked through in order.

Step 1: Is There a Defined Medical Indication?

Rare inherited disorders of NAD+ metabolism, such as NADSYN1-related congenital NAD deficiency disorder, represent the only plausible clinical context in which a pediatrician might consider NAD+ precursor supplementation in a child. A 2021 report in Genetics in Medicine described NMN supplementation in a neonate with NADSYN1 deficiency, representing one of the few pediatric case reports in the literature. That is a structured metabolic disease context. Performance enhancement, longevity, or general wellness are not defined medical indications in a 16-year-old.

If no defined indication exists, the risk-benefit calculation shifts strongly toward declining to recommend supplementation.

Step 2: Is the Adolescent's NAD+ Status Actually Low?

No validated reference range for blood NAD+ in healthy adolescents exists in peer-reviewed literature as of 2025. The NIH's Office of Dietary Supplements notes that standard clinical laboratories do not routinely measure NAD+, and interpretive norms for the 12-to-17 age bracket have not been established. Without a documented deficiency, supplementation addresses a problem that has not been confirmed to exist.

Step 3: What Are the Theoretical Risks Specific to This Age Group?

Several mechanistic concerns apply, even though none have been confirmed in human adolescent studies.

NAD+ feeds PARP enzymes that repair DNA strand breaks. In rapidly dividing adolescent tissues, particularly bone marrow, gonads, and the still-myelinating central nervous system, any pharmacological alteration of PARP activity could theoretically affect normal cellular checkpoints. This concern is speculative but biologically grounded. Preclinical work in Cell Metabolism by Cantó et al. (2012) established that NAD+ flux modulates SIRT1 and AMPK signaling in ways that affect cell-cycle progression, making the theoretical concern worth acknowledging.

Hormonal axis interaction is a second consideration. Sirtuin-1, activated by rising NAD+ levels, modulates gonadotropin-releasing hormone (GnRH) pulsatility in animal models. Whether exogenous NMN or NR doses achievable in humans affect pubertal hormone dynamics in adolescents is entirely unknown.

Step 4: What Does Shared Decision-Making Require?

If a parent and adolescent proceed after understanding steps 1 through 3, the clinician's responsibilities include: documenting the off-label conversation, establishing a baseline metabolic panel, agreeing on a monitoring interval (a reasonable starting point is 12 weeks), and specifying a dose at the conservative low end of the adult range (100 to 300 mg/day NMN or NR). These parameters reflect the principle described in the FDA's own guidance on pediatric off-label use documentation.

Safety Signals and Adverse Event Data

What Adult Data Can and Cannot Tell Us

The safety profile in adults is generally clean. Across published trials, the most common adverse events are mild nausea, flushing (more common with plain nicotinamide or niacin than with NMN or NR), and transient headache. Hepatotoxicity has not been reported at doses below 1,200 mg/day in trials of 12 weeks or less.

No pharmacokinetic studies have been conducted in adolescents to determine whether weight-based dosing or age-adjusted clearance rates differ from adults. Hepatic CYP enzyme activity varies by pubertal stage, which could alter the metabolic handling of NMN or its breakdown products. The FDA's pediatric pharmacokinetics guidance explicitly identifies pubertal stage as a variable that affects drug disposition.

Supplement Contamination Risk

Because NMN and NR are sold as dietary supplements rather than regulated drugs, manufacturing quality varies considerably. A 2023 independent analysis by ConsumerLab found that several NMN products contained less than 80 percent of labeled NMN content, and two products contained detectable heavy metal contamination. Adolescents, whose organ systems are still maturing, may be more susceptible to contaminant exposures than adults. Recommending third-party certified products (NSF International, USP, or Informed Sport) reduces but does not eliminate this risk.

What Clinicians and Parents Should Say to Each Other

Parental inquiries about NMN and NR for teenagers tend to come from two directions: parents who are themselves taking these compounds and wonder whether the benefits extend to their children, and parents of teens with fatigue, athletic performance goals, or mitochondrial-related diagnoses who have encountered supplement marketing.

A direct clinical response might follow this pattern: "The adult safety data up to 1,200 mg/day over 12 weeks are reassuring, but no trial has enrolled anyone under 20. We don't know if the dose needs to be adjusted for a developing body, and we don't know whether raising NAD+ in a teenager affects the same pathways it affects in an adult. If your child has a confirmed metabolic condition, let's look at that specifically. For general wellness in a healthy teen, the evidence doesn't support starting supplementation."

The American Academy of Pediatrics has not issued a specific position statement on NMN or NR as of 2025, but its general guidance on dietary supplements in children and adolescents encourages physicians to ask about supplement use at every well-child visit, to counsel families about the lack of regulatory oversight, and to report adverse events through MedWatch.

Emerging Research and What to Watch For

Active Investigations

As of early 2025, ClinicalTrials.gov lists no completed randomized trials of NMN or NR in participants under 18. A small number of observational registries have enrolled adolescents with rare mitochondrial diseases who were already receiving NAD+ precursors as part of compassionate-use protocols, but peer-reviewed results from these registries have not been published.

Biomarker Work Needed

Establishing a pediatric NAD+ reference range is the foundational step that would make any future efficacy or safety trial interpretable. Without it, researchers cannot determine whether an intervention raises NAD+ into a therapeutic zone or overshoots it. NIH's National Institute on Aging has funded NAD+ metabolomics work in aging adults, but no analogous funding for pediatric reference ranges has been publicly announced.

Regulatory Trajectory

The FDA's 2022 NMN enforcement stance is under ongoing legal challenge from supplement manufacturers. If NMN moves fully into the drug category, any clinical use in adolescents would require an investigational new drug (IND) application and IRB-approved protocol, raising the evidentiary bar significantly. Clinicians who currently discuss NMN with families should monitor the FDA's Dietary Supplement Ingredient Directory for updates.